Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating income | -$24.1M | -$41.7M | -$51.4M | -$38.8M | -$83.5M | -$105M | -$120M |
| Net income | -$23.5M | -$41.4M | -$51.4M | -$37.7M | -$71.6M | -$89.0M | -$104M |
| EPS (diluted) | -$33.40 | -$3.53 | -$2.37 | -$12.05 | -$2.01 | -$1.89 | -$1.83 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.9M | -$37.4M | -$46.8M | -$32.1M | -$61.3M | -$73.2M | -$70.3M |
| Capital expenditures | $140K | $18.0K | $12.0K | $612K | $149K | $44.0K | $158K |
| Free cash flow | -$22.0M | -$37.4M | -$46.8M | -$32.7M | -$61.4M | -$73.2M | -$70.5M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.94M | $47.7M | $48.3M | $75.5M | $100M | $124M | $98.9M |
| Total assets | $33.3M | $90.8M | $93.6M | $83.3M | $272M | $326M | $476M |
| Total liabilities | $4.38M | $6.41M | $7.62M | $10.4M | $26.0M | $15.9M | $16.6M |
| Shareholders' equity | -$48.8M | $84.4M | -$42.9M | -$76.8M | $246M | $310M | $460M |
| Retained earnings | -$54.8M | -$96.1M | -$147M | -$82.9M | -$154M | -$243M | -$347M |
| Shares (wtd avg diluted) | 703K | 17.5M | 21.7M | 3.12M | 35.5M | 47.1M | 56.7M |
Every figure is extracted from Enliven Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.